Press Releases Integrum AB

Equities

INTEG B

SE0009807266

Delayed Nasdaq Stockholm Other stock markets 08:31:42 2024-05-23 am EDT			5-day change	1st Jan Change
53.2 ^SEK	-0.37%		-2.56%	+16.54%

May. 15	Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu	CI
May. 02	Integrum Expands Its Product Offering to the United Kingdom Market	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Integrum has been granted a registered trademark for OPRA® Implant System in the EU	May. 15	AQ
Integrum launches short video documentary to showcase the company's efforts to treat combat amputees in Ukraine	May. 03	AQ
Integrum expands its product offering to the United Kingdom market	May. 02	AQ
Integrum: CBPR operations suspended	Apr. 26	AQ
Integrum: Anchoring its position as niche leader	Apr. 11	AQ
Integrum expands its product offering into the Israeli market	Mar. 26	AQ
Health economic study shows positive outcome using Integrum's OPRA[TM] Implant System over socket prostheses in transfemoral amputees	Mar. 19	AQ
Integrum Q3 - In line and no estimate changes	Mar. 01	AQ
A new record revenue quarter with 61% growth	Feb. 29	AQ
Integrum AB, Invitation to the Third Quarter 2023, 24 Results Presentation	Feb. 26	AQ
Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation	Feb. 23	AQ
Integrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine	Jan. 31	AQ
Integrum establishes Center of Excellence in Ukraine	Dec. 20	AQ
Integrum's MDR certification is completed for the OPRA[TM] Implant System	Dec. 15	AQ
Integrum Q2 - Alive and kicking	Dec. 05	AQ
Record sales and profitability	Dec. 04	AQ
Integrum AB changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Integrum AB: Invitation to the Second Quarter 2023/24 Results Presentation	Nov. 28	AQ
Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data	Nov. 13	AQ
Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023	Nov. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Integrum AB

Equities

INTEG B

SE0009807266

Press Releases

Filters